Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Reaffirmed by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday, Benzinga reports. They currently have a $173.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 23.42% from the company’s previous close.

A number of other research analysts have also recently commented on the stock. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a report on Wednesday, December 20th. They issued a “buy” rating and a $150.00 target price for the company. Wedbush increased their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Finally, Citigroup increased their target price on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.25.

Ascendis Pharma A/S Stock Down 0.5 %

ASND opened at $140.17 on Thursday. Ascendis Pharma A/S has a twelve month low of $66.03 and a twelve month high of $161.00. The company has a 50-day simple moving average of $149.17 and a 200 day simple moving average of $124.21. The stock has a market capitalization of $8.16 billion, a price-to-earnings ratio of -15.15 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The business had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.19 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. increased its position in Ascendis Pharma A/S by 14.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 282 shares during the period. Rice Hall James & Associates LLC increased its position in Ascendis Pharma A/S by 35.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 134,900 shares of the biotechnology company’s stock valued at $15,832,000 after purchasing an additional 35,039 shares during the period. Bank of New York Mellon Corp increased its position in Ascendis Pharma A/S by 20.5% during the 1st quarter. Bank of New York Mellon Corp now owns 289,344 shares of the biotechnology company’s stock valued at $33,958,000 after purchasing an additional 49,298 shares during the period. BlackRock Inc. increased its position in Ascendis Pharma A/S by 25.3% during the 1st quarter. BlackRock Inc. now owns 401,084 shares of the biotechnology company’s stock valued at $47,070,000 after purchasing an additional 80,988 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $14,083,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.